P2RY12 and atrial fibrillation: Four large randomised controlled trials (RCTs) investigating the efficacy and safety of dual antithrombotic therapy (NOAC + P2Y12 inhibitor) versus triple therapy (OAC [VKA or NOAC] + P2Y12 inhibitor + aspirin) have been conducted with AF patients undergoing PCI so far4–8.